Johnson & JohnsonJNJ
JNJ
0
Funds holding %
of 6,814 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
115% more first-time investments, than exits
New positions opened: 226 | Existing positions closed: 105
22% more call options, than puts
Call options by funds: $3.21B | Put options by funds: $2.62B
15% more funds holding in top 10
Funds holding in top 10: 163 [Q2] → 188 (+25) [Q3]
8% more capital invested
Capital invested by funds: $261B [Q2] → $281B (+$20B) [Q3]
2% more funds holding
Funds holding: 3,733 [Q2] → 3,803 (+70) [Q3]
2.22% less ownership
Funds ownership: 73.93% [Q2] → 71.71% (-2.22%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 1,518 | Existing positions reduced: 1,703
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$162
13%
upside
Avg. target
$179
25%
upside
High target
$215
50%
upside
8 analyst ratings
4 positive
50%
4 neutral
50%
0 negative
0%
Citigroup Joanne Wuensch 62% 1-year accuracy 29 / 47 met price target | 22%upside $175 | Buy Maintained | 11 Dec 2024 |
B of A Securities Tim Anderson 33% 1-year accuracy 2 / 6 met price target | 16%upside $166 | Neutral Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 33%upside $190 | Outperform Initiated | 15 Nov 2024 |
Guggenheim Vamil Divan 40% 1-year accuracy 8 / 20 met price target | 13%upside $162 | Neutral Maintained | 6 Nov 2024 |
Wells Fargo Larry Biegelsen 52% 1-year accuracy 24 / 46 met price target | 16%upside $166 | Equal-Weight Maintained | 16 Oct 2024 |
Financial journalist opinion
Based on 64 articles about JNJ published over the past 30 days
Positive
Market Watch
3 hours ago
Johnson & Johnson makes $15 billion bet on mental-health drugs
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts' expectations through 2029.
Positive
Reuters
4 hours ago
J&J to buy Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
Neutral
Business Wire
4 hours ago
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value.
Positive
The Motley Fool
5 hours ago
2 Beaten-Down Dividend Stocks to Buy in 2025
Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This description fits several dividend stocks on the market, among which are CVS Health (CVS 4.35%) and Johnson & Johnson (JNJ -0.15%).
Positive
Proactive Investors
6 hours ago
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition since Pfizer's $43bn purchase of Seagen in 2023.
Positive
Reuters
18 hours ago
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Neutral
Accesswire
1 day ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Johnson & Johnson (JNJ)
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.
Neutral
Seeking Alpha
2 days ago
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a "Buy" for its stability and consistent dividends, despite short-term price fluctuations and modest growth expectations. Q3 2024 results showed a 5.2% sales increase but a significant decline in earnings, highlighting mixed performance across segments. The company's strong economic moat, stable margins, and high return on invested capital support its long-term investment appeal.
Neutral
Accesswire
2 days ago
JNJ ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Johnson & Johnson investment
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Charts implemented using Lightweight Charts™